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Abstract
Benzimidazole, which is a heterocyclic nucleus, plays an important role in various 
medicines. A number of therapeutic agents such as H1 antihistaminic agent clemizole, 
a potent opioid analgesic etonitazene, nonnucleoside antiviral compound enviroxime, 
for promotion of excretion of uric acid irtemazole, non sedating antihistaminic agent 
astemizole, anti ulcer drugs omeprazole and pentoprazole, antihelmintic thiabendazole, 
antinematodal nocodazole etc. are based on benzimidazole heterocyclic nucleus. The 
synthesis of various benzimidazole derivatives by the reaction of ortho phenylene 
diamine I with various organic acids to yield 2-substituted benzimidazole derivatives 
II which on further treatment with nitric acid and sulphuric acid yielded 5-nitro-2-
substituted benzimdazoles III. Coupling of this compound with halogenated beta 
picoline V yielded the title compounds. The structures of synthesized compounds 
were elucidated mainly by spectral evidence. All the compounds were screened for 
their anti-hypertensive activity. The compounds exhibited moderate to significant 
activities.
Key Words: Synthesis, benzimidazoles, anti-inflammatory activity, anti-convulasant 
activity
1 INTRODUCTION
Cardiovascular diseases are a cause of significant number of mortalities among deaths reported due to various diseases. One of the most common ailments of cardiovascular system is hypertension. A patient 
as per guidelines is said to be hypertensive when blood pressure measures of 
140/90mmHg (systolic/diastolic pressure). Hypertension also involves slow 
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degenerative changes of vascular system of body leading to haemorrhage 
of arteries of vital organs leading to serious fatal consequences. Some of 
clinical strategies involved in the treatment of hypertension are diuretics, beta 
adrenergic blockers, aldosterone antagonist and ACE inhibitors.
Imidazole is a planer five-member heterocyclic ring with 3C and 2N 
atom and in ring N is present in 1st and 3rd positions. The imidazole ring is a 
constituent of several important natural products, including purine, histamine, 
histidine and nucleic acid. Being a polar and ionisable aromatic compound, 
it improves pharmacokinetic characteristics of lead molecules and thus used 
as a remedy to optimize solubility and bioavailability parameters of proposed 
poorly soluble lead molecules. Imidazole derivatives have occupied a unique 
place in the field of medicinal chemistry. The incorporation of the imidazole 
nucleus is an important synthetic strategy in drug discovery (Kumari, S., et al., 
2010). Substituted imidazoles are reported to posess a number of significant 
and diverse biological activities including antihistaminic (Aranjo, C. V. et al., 
2008), analgesic (Castro, I.O and Galvao, P.A.A. 1977), anti ulcer (Briseno-B, 
G. et al., 1977), antiviral (Pandey, V.K. et al., 2005; Jerchee, D. and Leibigs, 
F. H, 1952, and Kholer, P. 2001) antihelmintic (Freyne, E.J.E. et al., 1988), 
anti-hypertensive (Levin, J. et.al, 1944; Bradhury, R.H. et al., 1992), anti 
inflammatory (Hamor, G.H, 1986), and gout curing properties (Hamor, G.H, 
1986). A large number of therapeutic agents have been synthesized from 
imidazole nucleus which has demonstrated considerable potency. Moreover 
there is an increasing demand for novel therapeutic agents with significant anti-
hypertensive activity and fewer side effects. So, as a part of our programme of 
synthesis and biological evaluation of imidazole derivatives (Dureja, H., et al., 
2002 and Balakumar, P. et al, 2005), it was decided to synthesize some novel 
derivatives of imidazole by coupling them with alpha picoline and evaluate 
them for anti-hypertensive activity.
2 EXPERIMENTAL
2.1 Material and Methods
All the chemicals and reagents used were of Analar grade and were procured 
from M/s S.D. Fine Ltd, India, M/s Otto Ltd, India and Sigma Chemicals 
Co., USA. All the solutions used for the synthesis were prepared by using 
distilled water. Melting points were determined by using open capillary 
method and are uncorrected. The IR spectra of compounds were recorded on 
Perkin Elmer Infra Red Spectrophotometer in KBr disc and absorption bands 
are expressed in cm-1. NMR spectra were recorded on Brucker AC 300F 
(300 MHz) spectrometer using TMS as internal standard. Reactions were 
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monitored by thin layer chromatography on pre-coated plates using different 
solvent systems. The purity of synthesized compounds was ascertained by 
TLC using iodine vapours as visualizing agents. The blood pressure was 
recorded on Powerlab/4SP Data Acquisition, AD Instruments Pvt. Ltd. 
Australia. 
2.2 Synthesis
2.2.1 2-Substituted Benzimidazoles IIIa-IIIe
Ortho phenylene dia mine (I) (0.25 M) and appropriately substituted organic 
acids (II) (0.5 M) were reacted by heating under reflux for 6-13 h. The reaction 
mixture was cooled and basified to a pH of 7-8. The crude product so obtained 
(III) was dissolved in 95% ethanol and was suitably digested with activated 
charcoal. The boiling water was then added to the filtrate till the appearance 
of slight turbidity. The solution was made clear by adding a few drops of 



















































Figure 1: Synthetic Scheme-1
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2.2.2 5-Nitro 2-Substituted Benzimidazoles (IIIf-IIIj)
Concentrated nitric acid (7.5 mL) was placed in 3-necked RBF fitted with a 
mechanical stirrer. The flask was immersed in ice cold water and concentrated 
sulphuric acid (7.5 mL) was added slowly down the condensor with slow 
stirring. Afterwards, 2-substituted benzimidazole derivative (IIIa-IIIe) was 
added in portion over a period of 1h at such a rate that the temperature did not 
exceed 350C. After continuous stirring for 10-13 h, the reaction mixture was 
poured very slowly over crushed ice with vigorous stirring. The product (IIIf-
IIIj) was filtered and washed with cold water. 
2.2.3 Bromo methyl Pyridine (V)
Reaction of 2-methyl pyridine (IV) (0.25 M) with N-bromo succinamide 
(NBS) (0.25 M) and benzolyl peroxide (0.25 M) in CCl
4
 for 8.3 h yielded the 
product (V), which was filtered and cooled overnight at room temperature. 
2.2.4 Title Compounds (VIa-VIj)
Appropriately substituted benzimidazole (III) (0.1 M) was dissolved in 
Dimethyl formamide (DMF) a nd 2.5 g potassium carbonate. The mixture 
was stirred vigorously at room temperature on a mechanical stirrer for 1 h. 
To the reaction mixture, a suspension of Bromomethyl pyridine (V) (0.1M) 
in DMF was added dropwise with stirring for 1h. The reaction mixture was 
Table 1: Physical and analytical data of synthesized compounds
Comp. No. R M.P. 
(°C)
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Table 2: Spectral data of Synthesized Compounds
Compd IR (KBr) cm-1 H1 N.M.R. (CDCl3)
VIa 3097 (Aromatic C-H Stretch); 2944 
(Aliphatic C-H Stretch); 1933, 1896 (Di-
substituted benzene); 1703 (C=N Stretch); 
1587 (C=C Stretch); 1458 (CH
2
bending); 
1245 (C-N Stretch); 746 (Ortho 
disubstituted benzene (oop))
δ = 8.90 (1H, s, -CH Imidazole); 
8.31 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.76 (2H, s, -CH2 
linker); 6.9-7.74 (7H, m, Aromatic 
protons)
VIb 3114 (Aromatic C-H Stretch); 2980 
(Aliphatic C-H Stretch); 1918, 1876 (Di-
substituted benzene); 1655 (C=N Stretch); 
1555 (C=C Stretch); 1450 (CH
2
 bending); 
1350.9(CH3 bending); 1270 (C-N Stretch); 
734 (oop)
δ = 8.31 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.76 (2H, s, -CH2 
linker); 7.0-7.64 (7H, m, Aromatic 
protons); 2.66 (s, 3H, -CH3)
VIc 3053 (Aromatic C-H Stretch); 2973 
(Aliphatic C-H Stretch); 1919, 1771 (Di-
Substituted benzene); 1621 (C=N Stretch); 





 bending); 1270 (C-N Stretch); 
741 (oop)
δ = 8.03 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.74 (2H, s, -CH
2
 
linker); 6.8-7.55 (7H, m, Aromatic 
protons); 2.97 (q, 2H, -CH
2




VId 3050 (Aromatic C-H Stretch); 2928 
(Aliphatic C-H Stretch); 1923, 1771 (Di-
Substituted benzene); 1622(C=N Stretch); 





 bending); 1260 (C-N Stretch); 
747 (oop)
δ = 8.60 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.76 (2H, s, -CH
2
 
linker); 6.70-7.54 (7H, m, Aromatic 
protons); 2.92 (t, 2H, -CH2), 1.88 
(m, 2H, -CH
2
), 1.04 (t, 3H, -CH
3
)
VIe 3140 (Aromatic C-H Stretch); 2928 
(Aliphatic C-H Stretch); 1929, 1889 (Di-
substituted benzene); 1622 (C=N Stretch); 





 bending); 1271 (C-N Stretch); 
745 (oop)
δ = 8.60 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.77 (2H, s, -CH
2
 
linker); 6.82-7.57 (7H, m, Aromatic 
protons); 2.97 (t, 2H, -CH
2
), 1.85 (m, 
2H, -CH
2






VIf 3103 (Aromatic C-H Stretch); 2815 
(Aliphatic C-H Stretch); 1901, 1773 (Di-
substituted benzene); 1623 (C=N Stretch); 
1591 (C=C Stretch); 1513, 1480 (-N=O 
aromatic stretch);1345 (C-N Stretch); 741 
(oop)
δ = 8.60 (1H, s, -CH imidazole), 
8.16 ( 1H, s, -CH at β to nitrogen of 
imidazole & α to carbon containing 
nitro group), 7.90 (1H, d, -CH at α 
to nitrogen in pyridine ring); 4.72 
(2H, s, -CH
2
 linker); 6.32-7.60 (5H, 
m, Aromatic protons)
VIg 3107 (Aromatic C-H Stretch) ; 2919 
(Aliphatic C-H Stretch); 1901, 1706 (Di-
Substituted benzene); 1630 (C=N Stretch); 
1592 (C=C Stretch); 1512, 1490 (-N=O 
aromatic stretch); 1418 (CH2 bending); 
1383 (CH
3
 bending); 1270 (C-N Stretch); 
738 (oop)
δ = 8.50 ( 1H, s, -CH at β to 
nitrogen of imidazole & α to carbon 
containing nitro group),
8.10 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.2 (2H, s, -CH
2
 
linker); 6.30-7.44 (5H, m, Aromatic 
protons); 2.95 (3H, s, -CH
3
)
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Compd IR (KBr) cm-1 H1 N.M.R. (CDCl3)
VIh 3095 (Aromatic C-H Stretch); 2982 
(Aliphatic C-H Stretch); 1895, 1755 (Di-
Substituted benzene); 1671 (C=N Stretch); 
1591 (C=C Stretch); 1517, 1490 (-N=O 





 bending); 1274 (C-N Stretch); 
737 (oop)
δ = 8.45 ( 1H, s, -CH at β to 
nitrogen of imidazole & α to carbon 
containing nitro group),
8.12 (1H, d, -CH at α to nitrogen 
in pyridine ring); 4.55 (2H, s, -CH
2
 
linker); 6.09-7.57 (5H, m, Aromatic 






VIi 3102 (Aromatic C-H Stretch); 2965 
(Aliphatic C-H Stretch); 1912, 1772 (Di-
substituted benzene); 1628 (C=N Stretch); 
1595 (C=C Stretch); 1517, 1441 (-N=O 
stretch); 1440 (CH
2
 bending); 1384 (CH
3
 
Bending); 1265(C-N-stretch); 738 (oop)
δ = 8.45 ( 1H, s, -CH at β to 
nitrogen of imidazole & α to carbon 
containing nitro group), 8.10 (1H, 
d, -CH at α to nitrogen in pyridine 
ring); 4.85 (2H, s, -CH
2
 linker); 6.1-
7.58 (5H, m, Aromatic protons); 2.69 
(2H, q, -CH
2
); 1.94 (2H, m, -CH
2
); 
1.03 (3H, t, -CH
3
)
VIj 3140 (Aromatic C-H Stretch); 2960 
(Aliphatic C-H Stretch); 1889, 1363 (Di-
substituted benzene); 1672 (C=N Stretch); 
1594 (C=C Stretch); 1513, 1441 (-N=O 
Stretch); 1470 (CH
2
 bending); 1310 (CH
3
 
Bending); 1223(C-N stretch); 737 (oop)
δ = 8.47 ( 1H, s, -CH at β to 
nitrogen of imidazole & α to carbon 
containing nitro group), 8.15 (1H, d, 
-CH at α to nit
rogen in pyridine ring); 4.1 (2H, 
s, -CH
2
 linker); 5.9-7.57 (5H, m, 
Aromatic protons); 2.94 (2H, q, 
-CH
2
); 2.45 (2H, m, -CH2); 1.98 
(2H, m,-CH
2
); 1.05 (3H, t, -CH
3
)
allowed to proceed further for 10-23 h and the excess solvent was removed 
under vacuum. The residue thus obtained was treated with 20 mL dilute HCl 
and extracted with ethyl acetate given in Synthetic scheme-1. The organic 
layer was washed with brine solution and dried over anhydrous sodium 
sulphate. The solvent was evaporated under reduced pressure to afford the 
product (VI) as a brownish amorphous solid. Physical and analytical data of 
synthesized compounds is summarized in Table-1 and characterization data 
in Table-2.
2.3 Structure Activity Relationship
The biphenyl benzimidazoles have potent antihypertensive action as 
compared to the previous related drugs due to better availability upon the oral 
administration, 2- position of biphenyl is essential for the activity (Walia, R. 
et al., 2011). 5 substituted aryl or alkyl caboxamido derivatives have reported 
to possess Angiotensin-II AT1 receptor antagonistic activity so are good 
antihypertensives agents (Shah, D. et al, 2007).
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3 BIOLOGICAL SCREENING
3.1 Spontaneous hypertensive rats (SHRs) of 200±20g body weight were 
used in study
Animals were procured from Laboratory Haryana agricultural university, 
Hissar. All animals were kept in polyacrylic cages and maintained under 
standard housing conditions (room temperature 24-270C and humidity 60-
65% with 12:12 light: dark cycles). Food was provided in the form of dry 
pellets and water ad libitum. All experiments involving animals complies with 
the ethical standards of animal handling and approved by Institutional Animal 
Ethics Committee (Approval number LSCP/IAEC/06/01).
Spontaneous hypertensive rats (SHRs) of 200±20g body weight were 
used. Rats were divided into 6 groups, each group had 6 animals. Animals 
in normal control and negative control groups received distilled water. Rats 
were anaesthetized by intraperitoneal injection of urethane (dose 1.6g/kg). 
The tracheotomy was cannulated to facilitate spontaneous respiration and 
artificial ventilation at tidal volume of 10ml/kg with stroke rate of 45/ml. The 
femoral vein was cannulated with polyethylene tubing for administration of 
test compounds. For measurement of haemodynamic parameters a cannula is 
inserted into artery femoral for continuous monitoring of blood pressure – mean 
arteriolar blood pressure (MAP) and heart rate. When stable haemodynamic 
conditions were achieved, adrenaline (1mg/kg i.v.) and isoprenaline (0.25 mg/
kg i.v.) were administered. When base line values again established, increasing 
doses of test substance was given intravenously. In case of no effect, the interval 
between successive doses was 15 min, otherwise 60 min. When base line 
values were again established, the dose of test samples (VIa-VIj) were given 
at dose of 20mg/kg, i.p in different groups and change in MAP was compared 
with prazocin (3mg/kg) treated group and vehicle treated control group. To 
check for α- or β-blocking activity adrenaline and isoprenaline administration 
is repeated after injection of the highest dose of test compound. If the test 
compound shows significant effect or no effect, a standard antihypertensive 
compound was administered for comparison purpose (Crestani, S. et.al, 
2011).
4 STATISTICAL ANALYSIS
The results are expressed as the mean± SEM for each group. Statistical 
differences were evaluated using a oneway analysis of variance (ANOVA) 
followed by Dunnett´s test. Results were considered to be statistically 
significant at p<0.05. 
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5 RESULTS AND DISCUSSION
The required starting material 2-substituted benzimidazole IIIa-IIIe was 
synthesized by reacting equimolar quantities of o-phenylene diamine I and 
appropriate organic acids i.e. acetic acid, formic acid, propionic acid, butyric 
acid and valeric acid. Compound II was nitrated at position 5 by adopting 
standard procedures. On the other hand, 3-methyl pyridine was heated under 
reflux with N-bromo succinimide (NBS) and benzoyl peroxide in CCl
4
 to yield 
bromomethyl pyridine V. Bromomethyl pyridine was coupled with 2- and 2,5- 
disubstituted benzimidazoles which yielded the title compounds. The result of 
the physico-chemical properties of all nineteen synthesized compounds is as 
shown in Table 1.
The compounds were obtained in good to excellent yield. The melting 
points of
Compounds varied from 50-168°C. The completion of each reaction was 
monitored by TLC spotting with the Rf values duly calculated. The structures 
of newly synthesized compounds were also elucidated by spectroscopic means 
which include IR, UV and NMR spectral studies as in Table 2. 
The biphenyl benzimidazoles have potent antihypertensive action as 
compared to the previous related drugs due to better availability upon the oral 
administration, 2- position of biphenyl is essential for the activity (Walia, R. 
et al., 2011). 5 substituted aryl or alkyl caboxamido derivatives have reported 
to possess Angiotensin-II AT1 receptor antagonistic activity so are good 
antihypertensives agents (Shah, D. et al, 2007). 
All the synthesized compounds were screened for anti-hypertensive 
activity. There were no significant differences in baseline blood pressure, 
heart rate or cardiac output between all experimental groups, as shown by 
ANOVA (P > 0.05). In the control group, the i.p. injection of the vehicle did 
not induce significant effects on the cardio-vascular parameters throughout the 
recording period.The i.p. injection of increasing doses of randomly selected 
ten derivatves of N, J, 3n4, 4n3 series(20 mg/kg) elicited short-lasting (1–3 
min) but dose-dependent hypotensive responses that were paralleled by 
reductions of MAP, SVR were of 26 ± 5% (n = 5, P < 0.05) accompanied 
by a slight reductions of the heart rate. The compounds VIh and VI J were 
found to be more active than standard while compounds VIg and VI i were 
found to be equipotent and others show significant activity but less than 
standard. Biological activity data of synthesized compounds is summarized 
in Table-3. 
Haemodynamic effects shown on Systolic blood pressure (SAP), Diastolic 
Blood pressure (DAP), Mean Arteriolar Pressure (MAP) and Heart Rate (HR) 
on SHRs treated with vehicle control and test compounds.
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Haemodynamic effects shown on Systolic blood pressure (SAP), Diastolic Blood 
pressure (DAP), Mean Arteriolar Pressure (MAP) and Heart Rate (HR) on SHRs treated with 
vehicle control and test compounds. Values were represented as mean ± SEM; n=5; *p<0.05 
vs baseline values.
6 SUMMARY
In the present investigation we reported the synthesis of ten novel substituted 
benzimidazoles. All the synthesized compounds were characterized by suitable 
spectroscopic methods such as IR and NMR. Purity of synthesized compounds 
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was ascertained by chromatographic methods (TLC and column). The synthesized 
compounds were evaluated for their anti-inflammatory and anti-convulsant 
potential. All the compounds demonstrated moderate to significant activity. In 
conclusion 5-nitro-2-substituted alkyl-1-(2-yl-pyridine) benzimidazoles may be 
explored further for their potential to act as therapeutically active compounds. 
All the synthesized compounds were screened for anti-hypertensive activity. 
There were no significant differences in baseline blood pressure, heart rate or 
cardiac output between all experimental groups, as shown by ANOVA (P > 
0.05) (Table 3). The compounds VIh and VI J were found to be more active 
than standard while compounds VIg and VI i were found to be equipotent and 
others show significant activity but less than standard.
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